Dec 13, 2023, 08:02 AM by

ome Biosciences, Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI). PGI enables the insertion of any DNA sequence, of any size, into any programmed genomic location. The Company has raised $213 million in Series A and B funding from investors: Andreessen Horowitz (a16z) Bio + Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments and others.

Dec 13, 2023, 08:02 AM by

Avalon Announces Better Way for Health Insurance Plans to Manage Growth and Costs of Genetic Testing

Dec 13, 2023, 08:02 AM by

AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.

Dec 13, 2023, 01:00 AM by User Not Found

Bio-IT World | The development of antibiotics for treating tuberculosis in the 1940s eventually closed the doors of high-altitude sanitoriums that had long been the best therapeutic option for millions of patients. In much the same way, researchers at the Buck Institute for Research on Aging hope to one day eliminate the need to admit people suffering from Alzheimer’s, Parkinson’s disease, and other age-related phenomena to a geriatric or psychiatric hospital.

Dec 12, 2023, 08:43 AM by

Carterra Inc. and ENPICOM B.V. announced today a collaboration to streamline the analysis of rapidly growing sequencing and antibody screening data generated in the lab.

Dec 12, 2023, 08:43 AM by

Distributing real-world data to researchers in hours instead of days

Dec 12, 2023, 01:00 AM by User Not Found

Bio-IT World | The development of antibiotics for treating tuberculosis in the 1940s eventually closed the doors of high-altitude sanitoriums that had long been the best therapeutic option for millions of patients. In much the same way, researchers at the Buck Institute for Research on Aging hope to one day eliminate the need to admit people suffering from Alzheimer’s, Parkinson’s disease, and other age-related phenomena to a geriatric or psychiatric hospital.

Dec 11, 2023, 08:54 AM by

BugBiome announced as the winner of the Discovery Spark life science business support programme and will be awarded a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures.

Dec 11, 2023, 08:54 AM by

Dec 8, 2023, 07:44 AM by

Dec 8, 2023, 07:44 AM by

Dec 8, 2023, 01:00 AM by User Not Found

Bio-IT World | For almost two decades, members of the life science community bemoaned something that most outsiders never realized: that the “finished” human genome assembly had never actually been finished. Now, thanks to remarkable efforts from the Telomere-to-Telomere (T2T) consortium, we finally have a complete human reference genome.

Dec 7, 2023, 08:06 AM by

Now InSysBio presents public beta release of fIVE Calculator which is a web application designed to automatically calculate kinetic parameters from in vitro experiments for modeling of biosystems.

Dec 7, 2023, 08:06 AM by

Dec 7, 2023, 08:06 AM by

Modernizing the 150-year-old microscope-based practice with digital innovation

Dec 7, 2023, 08:06 AM by

Dec 6, 2023, 09:21 AM by

Hi, I hope you are well. Please see below news from Recipharm on its collaboration with CRO, Oz-UK to accelerate the development of low global warming pressurised Metered Dose Inhalers (pMDIs). It has also announced the appointment of Simon Gardner, formerly of HFA-152a propellant supplier, Koura to support customers in their transition to greener propellants. Kind regards Char

Dec 6, 2023, 09:21 AM by

Dec 6, 2023, 01:00 AM by User Not Found

Bio-IT World | The “power of the team approach” was on full display for a study designed to understand the contribution of asymptomatic carriers to the spread of Clostridioides difficile in hospitals.

Dec 5, 2023, 08:05 AM by

DoseMe today announced the availability of its Cefepime model. This model will offer pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for Cefepime in critically ill patients, including those with unstable renal function, a common challenge faced by clinicians taking care of these complex patients.